Compare Dolby Laboratories, Inc. (DLB) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dolby Laboratories, Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? Dolby Laboratories, Inc. trades at $61.2 (market cap $5.75B), while State Street SPDR S&P Biotech ETF trades at $159.35. The key difference: Dolby Laboratories, Inc. pays a 2.35% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Dolby Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| DLB | XBI | |
|---|---|---|
Market Cap | $5.75B | — |
Sector | Industrials | Broad Market / Factor |
52-Week High | $75.62 | $164.28 |
52-Week Low | $48.51 | $86.92 |
Enterprise Value | $5.12B | — |
Dividend Yield | 2.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DLB trades at $61.39, down 1.14% today, with a bullish technical signal from moving averages and a consensus analyst price target of $87.50. The company has beaten EPS estimates for the last four quarters, including Q2 2026, and maintains strong profitability with an 87.61% gross margin. Recent news highlights growth in Dolby Atmos and auto licensing, though revenue declined year-over-year in Q3 2026.
The outlook is positive with analyst support and operational strength, but risks include licensing volatility and near-term execution challenges. The stock offers upside to the price target, supported by cash flow growth and market expansion in audio-visual technologies.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Dolby Laboratories, Inc.
Dolby Laboratories Inc develops audio and surround sound for cinema, broadcast, home audio systems, in-car entertainment systems, DVD players, games, televisions, and personal computers. The company generates three fourths of its revenue from licensing its technology to consumer electronics manufacturers around the world. The rest of revenue comes from equipment sales to professional producers and audio engineering services.
Read more on DLB →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
